Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
Alumis Inc. (ALMS)
Company Research
Source: GlobeNewswire
28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75Three additional data presentations further support ESK-001’s potential to offer a highly differentiated and best-in-class treatment profile for people with moderate-to-severe plaque psoriasisFull 52-week Phase 2 OLE dataset expected 1H 2025; Phase 3 clinical program ongoing SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive 28-week data from the open-label extension (OLE) period of its Phase 2 STRIDE clinical trial of ESK-001. These data were presented during a late-breaking oral session at the 2024 European Academy of Dermatology & Venereology (EADV) Congress held September 25-29
Show less
Read more
Impact Snapshot
Event Time:
ALMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALMS alerts
High impacting Alumis Inc. news events
Weekly update
A roundup of the hottest topics
ALMS
News
- Alumis Inc. (NASDAQ: ALMS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
- Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch [Yahoo! Finance]Yahoo! Finance
- Alumis to Participate in Upcoming September Investor ConferencesGlobeNewswire
- Alumis Inc. (NASDAQ: ALMS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate AchievementsGlobeNewswire
ALMS
Sec Filings
- 8/27/24 - Form SC
- 8/27/24 - Form 4/A
- 8/13/24 - Form 10-Q
- ALMS's page on the SEC website